Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increased risk of infusion-related reactions.

Schoof LG, Hogenboom L, van Kempen ZLE, Killestein J, van Oosten BW, Strijbis E M

Mult Scler J Exp Transl Clin. 2026 Apr-Jun; 12(2):20552173261449688. PMID: 42153199. Abstract